These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37042149)

  • 1. [Thoracic
    Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    PeerJ; 2024; 12():e16923. PubMed ID: 38374950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
    Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
    Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
    Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
    Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
    Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
    Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
    Nambirajan A; Jain D
    Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
    Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
    Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
    Zhou P; Fu Y; Tang Y; Jiang L; Wang W
    Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Subset of Thoracic SMARCA4-Deficient Undifferentiated Tumors Express GATA3.
    Coconubo DM; Wangsiricharoen S; Pettus JR; Linos K; Pinto A; Wang WL; Kerr DA; Cloutier JM
    Int J Surg Pathol; 2024 Jun; 32(4):684-691. PubMed ID: 37461275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature.
    Mundada M; Mannan KA; Vasu D; Ahmed F; K S
    Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
    Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
    Chatzopoulos K; Boland JM
    Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
    Rekhtman N; Montecalvo J; Chang JC; Alex D; Ptashkin RN; Ai N; Sauter JL; Kezlarian B; Jungbluth A; Desmeules P; Beras A; Bishop JA; Plodkowski AJ; Gounder MM; Schoenfeld AJ; Namakydoust A; Li BT; Rudin CM; Riely GJ; Jones DR; Ladanyi M; Travis WD
    J Thorac Oncol; 2020 Feb; 15(2):231-247. PubMed ID: 31751681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
    Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L
    Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric SMARCA4-deficient undifferentiated tumor (SMARCA4-UT): a clinicopathological analysis of four rare cases.
    Zhou P; Fu Y; Wang W; Tang Y; Jiang L
    Orphanet J Rare Dis; 2024 Jun; 19(1):237. PubMed ID: 38877473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report.
    Yang P; Xiong F; Lin Y; Liang P; Tang C
    Transl Cancer Res; 2023 Apr; 12(4):1041-1048. PubMed ID: 37180644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure.
    Shi L; Lin L; Ding Y; Zeng Y; Chen X
    Front Oncol; 2022; 12():1020875. PubMed ID: 36452500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.